Certara’s SWOT analysis: biosimulation firm’s stock faces growth hurdles

Certara, Inc. (NASDAQ:CERT), a leading provider of biosimulation software and AI-assisted drug development solutions with a market capitalization of $1.85 billion, has been navigating a complex landscape of opportunities and challenges in the rapidly evolving pharmaceutical industry. InvestingPro analysis indicates the company maintains a "GOOD" overall financial health score, positioning it well in the competitive landscape. As the company continues to position itself at the forefront of innovative drug discovery and development processes, investors and analysts are closely monitoring its performance and future prospects.

Company Overview and Market Position

Certara specializes in biosimulation and AI-assisted drug development, offering software and services designed to enhance the efficiency of drug discovery and development processes. The company’s solutions are increasingly relevant as the pharmaceutical industry seeks to reduce costs and accelerate time-to-market for new therapies.

In recent quarters, Certara has demonstrated resilience against industry headwinds, with its latest financial results showing a 10% year-over-year increase in revenue to $106.0 million for the first quarter of 2025. The company’s trailing twelve-month revenue stands at $394.5 million, with a healthy gross profit margin of 60.3%. This performance exceeded both analyst estimates and consensus expectations, underscoring the company’s ability to maintain growth in a challenging environment. Want deeper insights? InvestingPro subscribers have access to over 10 additional key metrics and expert analysis.

Financial Performance and Segment Analysis

Certara’s financial performance has been marked by steady growth across its two primary segments: software and services. The software segment, which includes the company’s core biosimulation offerings, has been a particular bright spot. In the first quarter of 2025, software revenue reached $46.4 million, representing an 18% year-over-year increase with organic growth of 4%.

The services segment, while growing at a more modest pace, still contributed significantly to the company’s overall performance. Services revenue for the same period stood at $59.6 million, a 4% year-over-year increase with organic growth of 3%.

Adjusted EBITDA for the first quarter of 2025 was $34.8 million, a 20% year-over-year increase, which surpassed analyst estimates and fell within the company’s preannouncement range of $33 million to $35 million. This strong EBITDA performance reflects Certara’s ability to maintain profitability while investing in growth initiatives.

Strategic Initiatives and Market Trends

Certara is strategically positioning itself to capitalize on several key industry trends. One of the most significant developments is the U.S. Food and Drug Administration’s (FDA) plans to phase out animal testing. This regulatory shift has increased interest in Certara’s non-animal navigator offerings, potentially opening up new growth avenues for the company.

The company is also making strides in developing its Cloud platform, aiming to offer a full suite of software across the clinical trial continuum. This initiative could enhance Certara’s competitive position and drive increased customer adoption and retention.

Analysts note that Certara’s management is committed to strategic investments and share repurchases, demonstrating confidence in the company’s future prospects. However, the company is also exploring strategic alternatives for its regulatory writing business, which has shown some weakness in recent periods.

Valuation and Competitive Landscape

Certara’s valuation has been a topic of discussion among analysts. According to InvestingPro data, the company currently trades at an EV/EBITDA multiple of 20.2x, with analysts setting price targets ranging from $13 to $18. Based on comprehensive analysis, InvestingPro’s Fair Value model suggests the stock is currently undervalued. The company trades at approximately 14 times its estimated 2025 EBITDA, which represents a discount compared to its peer Simulations Plus (NASDAQ:SLP), which trades at 19 times EBITDA. Some analysts believe that Certara should trade closer to SLP due to its broader offerings and have set target multiples accordingly.

The competitive landscape for Certara remains dynamic, with the company facing pressure from other biosimulation software providers and tech-enabled service companies. However, Certara’s broad range of solutions and strategic positioning in growth areas like non-animal testing alternatives provide potential competitive advantages.

Bear Case

How might declining net revenue retention impact Certara’s growth prospects?

Net revenue retention has been a concern for Certara, with sequential declines observed since the first quarter of 2024. This metric is crucial for software companies as it indicates the ability to retain and expand business with existing customers. A declining trend could signal challenges in customer loyalty or increased competitive pressures.

If this trend continues, it may hamper Certara’s organic growth prospects, potentially leading to slower revenue expansion and increased customer acquisition costs. The company may need to allocate more resources to customer retention strategies and product enhancements to reverse this trend and maintain its growth trajectory.

What risks does Certara face from potential regulatory changes in biosimulation data acceptance?

While the FDA’s move away from animal testing presents opportunities for Certara, there is also a risk associated with regulatory acceptance of biosimulation data. The company’s growth is partly predicated on the increasing use and acceptance of biosimulation in drug development processes.

Any reversal or slowdown in regulatory acceptance of biosimulation data could significantly impact Certara’s value proposition. This risk is compounded by the fact that regulatory environments can be unpredictable and subject to change based on various factors, including political pressures and emerging scientific evidence.

Bull Case

How could Certara’s positioning in non-animal testing solutions drive future growth?

Certara’s "Non-Animal Navigator (ELI:NVGR)" solution is well-positioned to capitalize on the FDA’s plans to phase out animal testing. This regulatory shift represents a significant opportunity for Certara to expand its market share and drive adoption of its biosimulation software.

As pharmaceutical companies seek alternatives to traditional animal testing methods, Certara’s solutions could become increasingly critical in the drug development process. This could lead to expanded contracts, new customer acquisitions, and potentially higher-margin business as the company’s offerings become more integral to drug development workflows.

What advantages does Certara’s broad range of solutions provide in the current market?

Certara’s comprehensive suite of software and services across the drug development continuum provides a competitive edge in the current market. This breadth of offerings allows the company to address multiple pain points in the drug development process, potentially increasing customer stickiness and cross-selling opportunities.

In an environment where pharmaceutical companies are looking to streamline their R&D processes and reduce costs, Certara’s integrated solutions could become increasingly attractive. The company’s ability to offer end-to-end support, from early-stage drug discovery to regulatory submission, positions it as a valuable partner for pharmaceutical and biotechnology firms of all sizes.

SWOT Analysis

Strengths:

• Strong growth in software bookings
• Broad range of biosimulation and AI-assisted drug development solutions
• Strategic positioning in non-animal testing alternatives
• Solid financial performance with consistent revenue growth

Weaknesses:

• Declining net revenue retention
• Weakness in regulatory services segment
• Potential need for strategic realignment of certain business units

Opportunities:

• FDA’s plans to phase out animal testing
• Increasing adoption of AI and biosimulation in drug development
• Expansion of Cloud platform offerings
• Potential for strategic acquisitions to enhance capabilities

Threats:

• Competitive pressures from other biosimulation software providers
• Regulatory risks related to acceptance of biosimulation data
• Potential industry-wide slowdown in biopharma R&D spending
• Macroeconomic headwinds affecting client budgets

Analysts Targets

• Barclays (LON:BARC) Capital Inc.: Overweight rating with a price target of $14 (May 9th, 2025)
• JMP Securities: Market Perform rating, no price target provided (May 6th, 2025)
• JMP Securities: Market Perform rating, no price target provided (February 27th, 2025)
• JMP Securities: Market Perform rating, no price target provided (November 7th, 2024)
• Barclays Capital Inc.: Equal Weight rating with a price target of $12 (November 7th, 2024)

Certara continues to navigate a complex landscape of opportunities and challenges in the biosimulation and AI-assisted drug development market. While the company faces headwinds in certain areas, its strategic positioning and innovative solutions provide a foundation for potential long-term growth. Investors and industry observers will be closely watching how Certara capitalizes on regulatory shifts and technological advancements in the coming years.

This analysis is based on information available up to May 25, 2025, and reflects the most recent analyst reports and company disclosures provided in the context. For comprehensive research and real-time updates, consider exploring InvestingPro, which offers exclusive insights, Fair Value estimates, and detailed financial metrics for informed investment decisions. Access the full Pro Research Report, available for over 1,400 US stocks, to transform complex Wall Street data into actionable intelligence.

InvestingPro: Smarter Decisions, Better Returns

Gain an edge in your investment decisions with InvestingPro’s in-depth analysis and exclusive insights on CERT. Our Pro platform offers fair value estimates, performance predictions, and risk assessments, along with additional tips and expert analysis. Explore CERT’s full potential at InvestingPro.

Should you invest in CERT right now? Consider this first:

Investing.com’s ProPicks, an AI-driven service trusted by over 130,000 paying members globally, provides easy-to-follow model portfolios designed for wealth accumulation. Curious if CERT is one of these AI-selected gems? Check out our ProPicks platform to find out and take your investment strategy to the next level.

To evaluate CERT further, use InvestingPro’s Fair Value tool for a comprehensive valuation based on various factors. You can also see if CERT appears on our undervalued or overvalued stock lists.

These tools provide a clearer picture of investment opportunities, enabling more informed decisions about where to allocate your funds.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.